Cargando…
Identification of serum protein biomarkers for utrophin based DMD therapy
Despite promising therapeutic avenues, there is currently no effective treatment for Duchenne muscular dystrophy (DMD), a lethal monogenic disorder caused by the loss of the large cytoskeletal protein, dystrophin. A highly promising approach to therapy, applicable to all DMD patients irrespective to...
Autores principales: | Guiraud, Simon, Edwards, Benjamin, Squire, Sarah E., Babbs, Arran, Shah, Nandini, Berg, Adam, Chen, Huijia, Davies, Kay E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333102/ https://www.ncbi.nlm.nih.gov/pubmed/28252048 http://dx.doi.org/10.1038/srep43697 |
Ejemplares similares
-
Second-generation compound for the modulation of utrophin in the therapy of DMD
por: Guiraud, Simon, et al.
Publicado: (2015) -
Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
por: Guiraud, Simon, et al.
Publicado: (2019) -
The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019) -
Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice
por: Kennedy, Tahnee L., et al.
Publicado: (2018) -
Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle
por: Kennedy, Tahnee L., et al.
Publicado: (2017)